CytoMed Therapeutics Limited (GDTC)Healthcare | Biotechnology | Singapore, Singapore | NasdaqCM
1.01 USD
-0.01
(-0.980%) ⇩
(April 17, 2026, 4 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:45 p.m. EDT
GDTC (CytoMed Therapeutics Limited) is a biotechnology stock with a highly volatile price history and negative fundamental indicators. The stock has shown significant fluctuations in the recent 14-day period, with a current price of $1.00, which is close to its 52-week low of $0.728. The stock's beta of -0.21 indicates it is inversely correlated with the market, which could be a risk factor in a rising market. The forward PE ratio is negative, suggesting the company is not currently profitable, and the trailing EPS is also negative. The stock has a low market cap of $11.8 million, which indicates it is a small-cap stock and may be more susceptible to market volatility. The recent news headlines suggest there is some optimism about the company's future, but the stock's fundamentals and financials are not strong. The stock does not pay dividends, which is a negative for dividend-focused investors. The forecasting model predicts a -13.92% price change over the next 45 days, which is a significant drop. Overall, GDTC is not a strong investment option for either short-term or long-term investors, and it is not a good choice for dividend investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.356152 |
| AutoARIMA | 0.421740 |
| MSTL | 0.436668 |
| AutoETS | 0.452155 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 14.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.145 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.041 |
| Revenue per Share | 0.074 |
| Market Cap | 11,951,163 |
| Forward P/E | -6.73 |
| Beta | -0.21 |
| Website | https://w2.cytomed.sg |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.55701756 |
| Address1 | 1 Commonwealth Lane |
| Address2 | No. 08-22 |
| All Time High | 9.25 |
| All Time Low | 0.728 |
| Ask | 1.04 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 5,480 |
| Average Daily Volume3 Month | 565,301 |
| Average Volume | 565,301 |
| Average Volume10Days | 5,480 |
| Beta | -0.21 |
| Bid | 1.0 |
| Bid Size | 1 |
| Book Value | 0.43431515 |
| City | Singapore |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Singapore |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.01 |
| Current Ratio | 5.165 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.02 |
| Day Low | 0.97 |
| Debt To Equity | 7.041 |
| Display Name | CytoMed Therapeutics |
| Earnings Timestamp End | 1,745,870,400 |
| Earnings Timestamp Start | 1,745,870,400 |
| Ebitda | -3,849,627 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.765 |
| Enterprise To Revenue | 12.363 |
| Enterprise Value | 10,643,013 |
| Eps Forward | -0.15 |
| Eps Trailing Twelve Months | -0.27 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.04088 |
| Fifty Day Average Change | -0.030879974 |
| Fifty Day Average Change Percent | -0.029667182 |
| Fifty Two Week Change Percent | -55.701756 |
| Fifty Two Week High | 3.68 |
| Fifty Two Week High Change | -2.67 |
| Fifty Two Week High Change Percent | -0.7255435 |
| Fifty Two Week Low | 0.728 |
| Fifty Two Week Low Change | 0.282 |
| Fifty Two Week Low Change Percent | 0.38736266 |
| Fifty Two Week Range | 0.728 - 3.68 |
| Financial Currency | SGD |
| First Trade Date Milliseconds | 1,681,479,000,000 |
| Float Shares | 3,967,730 |
| Forward Eps | -0.15 |
| Forward P E | -6.733333 |
| Free Cashflow | -2,715,337 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.89572996 |
| Gross Profits | 771,088 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.66431 |
| Held Percent Institutions | 0.0049 |
| Implied Shares Outstanding | 11,832,835 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-04-14 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore. |
| Long Name | CytoMed Therapeutics Limited |
| Market | us_market |
| Market Cap | 11,951,163 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_647650276 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -3,980,457 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,951,163 |
| Open | 1.02 |
| Operating Cashflow | -3,697,463 |
| Operating Margins | -5.3525 |
| Payout Ratio | 0.0 |
| Phone | 65 6250 7738 |
| Previous Close | 1.02 |
| Price Hint | 4 |
| Price To Book | 2.3255002 |
| Price To Sales Trailing12 Months | 13.883012 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.141 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.98039126 |
| Regular Market Day High | 1.02 |
| Regular Market Day Low | 0.97 |
| Regular Market Day Range | 0.97 - 1.02 |
| Regular Market Open | 1.02 |
| Regular Market Previous Close | 1.02 |
| Regular Market Price | 1.01 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 4,047 |
| Return On Assets | -0.29312 |
| Return On Equity | -0.50276 |
| Revenue Growth | 0.469 |
| Revenue Per Share | 0.074 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 11,832,835 |
| Shares Percent Shares Out | 0.0069999998 |
| Shares Short | 82,681 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 137,172 |
| Short Name | CytoMed Therapeutics Limited |
| Short Percent Of Float | 0.023699999 |
| Short Ratio | 8.24 |
| Source Interval | 15 |
| Symbol | GDTC |
| Total Cash | 2,095,489 |
| Total Cash Per Share | 0.177 |
| Total Debt | 482,562 |
| Total Revenue | 860,848 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.27 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.618065 |
| Two Hundred Day Average Change | -0.608065 |
| Two Hundred Day Average Change Percent | -0.37579763 |
| Type Disp | Equity |
| Volume | 4,047 |
| Website | https://w2.cytomed.sg |
| Zip | 149,544 |